Decitabine. SAFETY DATA SHEET. 10/28/2013. Supersedes Revision: according to Regulation (EC) No. 1907/2006 as amended by (EC) No. 1272/2008. 11166. DACOGEN safely and effectively. See full prescribing information for. DACOGEN. DACOGEN® (decitabine) for injection, for intravenous use. Initial U.S. . Supersedes date: 26/04/2017. SAFETY DATA SHEET. Decitabine. According to Regulation (EC) No 1907/2006, Annex II, as amended. Commission Regulation . Dacogen 50 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung. . Dacogen ist indiziert zur Behandlung erwachsener Patienten ab einem Alter . In a treatment cycle, Dacogen is administered at a dose of 20 mg/m2 bodysurface . Hypersensitivity to decitabine or to any of the excipients, listed in section 6.1. Decitabine is indicated for treatment of patients with myelodysplastic syndrome (MDS). It is a chemical analogue of cytidine, a nucleoside present in DNA and . 2 thg 5, 2006 - Dacogen™ (decitabine) for Injection is a white to almost white sterile . Each 20 mL, single dose, glass vial contains 50 mg decitabine, 68 mg. 29 thg 4, 2009 - 4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one ; Decitabine. Recommended Use. Laboratory chemicals. Uses advised . Section 1 - Chemical Product and Company Identification. MSDS Name: Synonyms: Company Identification: Decitabine Lyophilized powder for Injection. Material Safety Data Sheet of Decitabine contains identification of substance and details of the supplier of the safety data sheet.